Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Gulick

Showing results (51-60 of 155) with videos related to

Pageof 16
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2010
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, et al.
AIDS Care|April 12, 2024
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidatesJeremy Sugarman, Brian W Weir, Chen Dun, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug developmentBethany L Morris, Callie A Scott, Timothy J Wilkin, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
HIV Clinical Trials|May 18, 2007
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359Richard H Haubrich, Hongyu Jiang, Ronald Swanstrom, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START TrialIrini Sereti, Roy M Gulick, Sonya Krishnan, et al.
Annals of Internal Medicine|November 17, 2005
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsDavid B Clifford, Scott Evans, Yijun Yang, et al.
Pageof 16

Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2010
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, et al.
AIDS Care|April 12, 2024
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidatesJeremy Sugarman, Brian W Weir, Chen Dun, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug developmentBethany L Morris, Callie A Scott, Timothy J Wilkin, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
HIV Clinical Trials|May 18, 2007
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359Richard H Haubrich, Hongyu Jiang, Ronald Swanstrom, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START TrialIrini Sereti, Roy M Gulick, Sonya Krishnan, et al.
Annals of Internal Medicine|November 17, 2005
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsDavid B Clifford, Scott Evans, Yijun Yang, et al.
Pageof 16